BioMarin Pharmaceutical’s (BMRN) Neutral Rating Reiterated at HC Wainwright

Posted by Brian Himes on Nov 3rd, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $60.00 price target on the biotechnology company’s stock. HC Wainwright‘s price target suggests a potential upside of 8.97% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Morgan Stanley cut their price objective on BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 21st. UBS Group assumed coverage on BioMarin Pharmaceutical in a report on Thursday, October 15th. They set a “buy” rating and a $88.00 target price for the company. Citigroup raised their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Piper Sandler lifted their price target on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, September 1st. Finally, Oppenheimer reissued an “outperform” rating and set a $94.00 price objective (down from $97.00) on shares of BioMarin Pharmaceutical in a research report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $88.09.

Read Our Latest Report on BioMarin Pharmaceutical

BioMarin Pharmaceutical Trading Down 4.1%

Shares of BioMarin Pharmaceutical stock traded down $2.38 during trading on Tuesday, reaching $55.06. 1,499,676 shares of the stock were exchanged, compared to its average volume of 2,110,063. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The stock’s fifty day moving average is $60.43 and its 200 day moving average is $58.46. The firm has a market cap of $10.66 billion, a price-to-earnings ratio of 148.64, a price-to-earnings-growth ratio of 0.61 and a beta of 0.22. BioMarin Pharmaceutical has a 1 year low of $49.26 and a 1 year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last posted its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.31. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same period last year, the firm earned $0.12 earnings per share. BioMarin Pharmaceutical’s quarterly revenue was up 32.0% on a year-over-year basis. As a group, equities research analysts expect that BioMarin Pharmaceutical will post 2.59 earnings per share for the current fiscal year.

Institutional Trading of BioMarin Pharmaceutical

Several large investors have recently bought and sold shares of BMRN. Primecap Management Co. CA purchased a new position in BioMarin Pharmaceutical during the second quarter valued at $811,962,000. Caisse de depot et placement du Quebec bought a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $70,749,000. Bank of New York Mellon Corp bought a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $66,107,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth about $39,312,000. Finally, Palo Alto Investors LP purchased a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth about $39,068,500. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with expectations. Adjusted EPS was $0.23, well above the consensus estimate for a loss of roughly $0.08–$0.09. Growth was led by a 44% increase in metabolic-condition revenue and a 12% rise in skeletal-condition revenue. BioMarin Reports Third Quarter 2026 Financial and Operating Results
Positive Sentiment: The company added a new investigational Fabry disease asset to its clinical portfolio and reported a May 30, 2027 PDUFA action date for VOXZOGO in hypochondroplasia, supporting BioMarin’s longer-term growth story.
Positive Sentiment: Options activity was notably bullish, with traders purchasing 3,961 call options—about 228% above typical call volume—suggesting increased speculative interest in a potential rebound.
Neutral Sentiment: Analyst opinion remains mixed. Citi reiterated a Buy rating, while Royal Bank of Canada maintained a Sector Perform rating, indicating that near-term execution concerns are balanced against BioMarin’s pipeline potential.
Negative Sentiment: BioMarin lowered its 2026 adjusted EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and issued revenue guidance of $3.8 billion–$3.9 billion versus the $3.9 billion consensus. Management cited order-timing uncertainty and charges related to two acquired in-process research programs. BioMarin Q3 2026 Results and Guidance
Negative Sentiment: Royal Bank of Canada lowered its BMRN price target from $62 to $60 while retaining its Sector Perform rating, reinforcing investor concerns about limited near-term upside.

BioMarin Pharmaceutical Company Profile

(Get Free Report)

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.